Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Amid a Changing Global Landscape, Countries Seek Investment Opportunities at CIFIT

    September 12, 2026

    Ajman Department of Tourism, Culture & Media Showcases Emirate’s Tourism Offerings at Arabian Travel Market 2026

    September 12, 2026

    Zettabyte and Raku Advanced Tech Sign MOU on Green AI Data Centers Across Asia

    September 11, 2026
    Facebook X (Twitter) Instagram
    • Home
    • Contact Us
    Doha EzineDoha Ezine
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • More
      • Sports
      • Technology
      • Travel
    Doha EzineDoha Ezine
    Home » Innovative experimental malaria drug based on antibodies discovered
    Featured News

    Innovative experimental malaria drug based on antibodies discovered

    November 1, 2022
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email

    A new study in Africa has found that a one-time dose of an experimental drug protects adults against malaria for at least six months. In 2020, malaria killed more than 620,000 people and sickened 241 million, mostly children under 5. There is a malaria vaccine being rolled out by the World Health Organization for children, but it is only 30% effective and requires four doses.

    Innovative experimental malaria drug based on antibodies discoveredIn this new study, people received a large dose of lab-made malaria-fighting antibodies instead of relying on the immune system to make enough of those same infection-blockers after vaccination, reported the Associated Press (AP). “There are not enough people protected by the vaccine available,” said Kassoum Kayentao, a researcher from the University of Sciences, Techniques and Technologies in Bamako, Mali.

    In those villages, people are bitten by infected mosquitoes on average twice a day during malaria season, according to other research. Experimental antibody, developed by researchers at the US National Institutes of Health, was delivered by IV. In the meantime, an easy-to-administer shot version from the same scientists is in early testing in infants, children, and adults.

    Research presented at a medical meeting in Seattle was published Monday in the New England Journal of Medicine. In order to work, the antibody breaks the life cycle of the parasite, which is spread through mosquito bites. It targets immature parasites before they mature and multiply in the liver. An antibody taken from a volunteer who received a malaria vaccine was used to develop it.

    It involved 330 adults in Mali who received either a dummy infusion or two different antibody doses. Every two weeks for 24 weeks, all were tested for malaria infection. Treatment was provided to anyone who became ill. A blood test detected infections in 20 people who received the higher dose, 39 people who received the lower dose, and 86 people who received the placebo. Compared to the placebo, the higher dose was 88% effective. There was a 75% effectiveness rate for the lower dose.

    During a malaria season, protection might last for several months. In the future, it could be used in conjunction with other malaria prevention methods, such as malaria pills, mosquito nets, and vaccinations. According to one estimate, lab-made antibodies could be given for as little as $5 per child per malaria season.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email

    Related Posts

    D1 Management and Gulf Medical University Sign MoU to Advance Veterinary Education, Clinical Training and Scientific Research

    September 7, 2026

    No Competition Infinity Gaming Signs Five-Year China Agreement, Projects Up to 10,000 Humanoid Robots Annually

    September 2, 2026

    From Campus to GISEC Global: School of Cyber Defense Returns for 2026 in Collaboration with Dubai Electronic Security Center

    August 27, 2026

    Thumbay International Pathway – MD Program, With Installments and a Direct Route to Residency in Romania

    August 21, 2026

    Thumbay Group and UMFST G.E. Palade Targu Mures, Romania Launch Thumbay – UMFST International Residency Pathway Program, Opening the Door to 49 European Medical Specialties

    August 18, 2026

    TCL Extends its Global Leadership from Television to Air Conditioning with Launch of VoxIN JetMax in the UAE

    August 10, 2026
    Editor's Pick

    Apple iPhone Duo debuts with dual screens and A20 Pro

    September 10, 2026

    The iPhone Duo uses a book-style design with a precision hinge built from more than 100 components. Apple uses grade 5 titanium for the enclosure and Ceramic Shield materials on the exterior surfaces. The company gives the handset an IP68 rating for splash, water and dust resistance. Its inner display includes a nano-texture finish designed to reduce glare and reflections. Both displays support ProMotion, Always On features and peak outdoor brightness of 3,000 nits.

    Apple launches iPhone 18 Pro with A20 Pro and Siri AI

    September 10, 2026

    Gold stays above $4,400 before US inflation releases

    September 10, 2026

    UAE President opens Germany state visit with Berlin talks

    September 10, 2026

    Panama Canal weighs tighter transit cap amid drought

    September 9, 2026

    Ballon d’Or 2026 nominees confirmed for London ceremony

    September 9, 2026
    © 2026 Doha Ezine | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.